The future of Abeona Therapeutics depends heavily on the successful commercial scale-up and market adoption of Zevaskyn for recessive dystrophic epidermolysis bullosa, alongside the clinical progression of its broader cell and gene therapy pipeline assets, such as its engineered T-cell therapies designed to tackle solid tumors and other severe genetic indications.